You might want to invest in biotechnology, but be careful. It’s not an easy industry to master, and while some companies eventually skyrocket, many others flame out.One simple way to invest in biotech is the iShares Nasdaq Biotechnology ETF (Nasdaq: IBB), which is a fund of roughly 150 stocks that has grown by an annual average of almost 15 percent […]
Sovaldi pill. Source: Gilead SciencesGilead Sciences had another phenomenal year in 2014, returning 26% for investors. That’s more than double the return of the broad-based S&P 500 , and it has hepatitis C drug Sovaldi to thank.In just the first nine months of 2014, Sovaldi netted Gilead $8.55 billion in sales. It’s the most effective drug launch in history by […]
Life-changing financial gains are usually generated over the long haul, not in one year. However, sometimes stocks can put up eye-popping returns over a short period of time and when they do they can have a huge impact on investor’s portfolios. For example, these three healthcare stocks tripled investor’s money last year and while no one can know if they’ll […]
This healthcare edition of Industry Focus takes a look at three biotech stocks and why each company is positioned for a great performance in the coming year.If your portfolio could use some exposure to healthcare and biotechs, join the Fool’s Michael Douglass and Todd Campbell, along with special guest Kristine Harjes, to learn more about three promising stocks in the […]
SummaryThere has definitely been a sector rotation out of biotech stocks and into the consumer goods names that pay high dividend yields.
Amgen remains fairly valued based on 2015 earnings estimates.
The dividend is small but investors received a 29.5% increase to the dividend in the next quarter.
The last time I analyzed Amgen Inc. (NASDAQ:AMGN) on November 25, 2014, I stated, “More […]
Benchmarks mostly settled in the green on Tuesday banking on better-than-expected revision to third quarter GDP numbers. The Dow closed above the 18K mark for the first time ever and notched up a record closing level for the 36th time this year. Almost 119 trading sessions have gone by since the index had crossed the 17K mark. The S&P 500 […]
By Ben LevisohnRBC’s Michael Yee and team explain why Celgene (CELG), Biogen Idec (BIIB), Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN) and Regeneron Pharmaceuticals (REGN) are their top biotech stocks for 2015:
Bloomberg News
Top-five longs: Celgene, Biogen Idec, BioMarin Pharmaceutical, Vertex Pharmaceuticals, Regeneron Pharmaceuticals: 1) Celgene we predict “settlement” with Actavis (ACT) could happen after spring when expert discovery ends and before Court begins mid-15; plus investors should start giving […]
Many biotech stocks have been breaking out over the past two months.Newlink Genetics Corp and Incyte Corporation both skyrocketed in October.After that, stocks of Ariad Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. both had nice, quick pops last month.Then there was Kite Pharma Inc’s huge jump earlier this month.So, Who’s Next?The Company: Sangamo Biosciences, Inc.Ticker Symbol: (NASDAQ: SGMO)Sector: HealthcareIndustry: BiotechnologySangamo focuses […]
Source: Celgene CorporationThe biotechnology industry has been one of the best performing baskets in the stock market this year, but just because biotech stocks were kind to investors this year doesn’t necessarily mean that they’ll rally next year, too.Biotech stocks can move significantly higher or lower in any given year due to investor’s reaction to data from ongoing drug trials, […]
Biotechnology stocks have been among the market’s top performers this year, with the iShares Nasdaq Biotechnology ETF’s 36% gain handily outpacing the S&P 500 ‘s 14% return. That heady return, however, comes with one potential drawback: It might be tough to figure out which biotech stocks will continue climbing next year. With that in mind, here are three large-cap biotech […]
